Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

October 29, 2024

Kivu Bioscience secures $92m in Series A funding for ADC development

Kivu Bioscience has completed a $92m Series A funding round, spearheaded by Novo Holdings to propel the development of next-generation antibody-drug conjugates (ADCs).

Kivu Bioscience secures $92m in Series A funding for ADC development